Chemomab Therapeutics Ltd.
Close on Oct 19, 2026
- Market cap
- $749.09M
- P/E (TTM)
- 65.0
- Dividend yield
- –
About Chemomab Therapeutics
Pharmaceutical Preparations, SIC 2834
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for inflammatory and fibrotic disorders. The company designs targeted treatments centered primarily on antagonizing CCL24 signaling, a pathway that regulates inflammatory and fibrotic processes. Its pipeline is led by nebokitug (CM-101), an investigational drug candidate being evaluated in clinical studies for the treatment of primary sclerosing cholangitis and systemic sclerosis. Because nebokitug remains in clinical development, the company has no approved commercial products and does not currently generate revenue from commercial drug sales.
Chemomab operates primarily in Israel and the United States, and relies on third-party manufacturing facilities located across Europe to supply its clinical product candidates. The company maintains its principal executive offices in Tel Aviv, Israel, and conducts business operations as well as clinical development internationally.
Summary of the business section of Chemomab Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Chemomab Therapeutics Ltd.
- Founded
- 2011
- Headquarters
- Tel Aviv, Israel
- Address
- Kiryat Atidim, Building 7
- Phone
- 972-77-331-0156
- Website
- chemomab.com
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Somekh Chaikin, Tel Aviv, Israel
Stock & identifiers
- Ticker
- CMMB
- Exchange
- Nasdaq
- IPO date
- Feb 12, 2019
- Shares outstanding
- 575M, Dec 31, 2025
- Public float
- $37.90M, Dec 31, 2022
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Aug 26, 2025; 7-for-2, May 13, 2021; 1-for-16 reverse, Mar 17, 2021
- SEC CIK
- 1534248
- CUSIP
- 16385C203
- ISIN
- US16385C2035
- LEI
- 894500LSC3H1WGG6LV25
- EIN
- 81-3676773
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| George Adi Mor | Chief Executive Officer, Director | 68,809 |
| Sigal Fatal | Chief Financial Officer | 12,500 |
| John Lawler | Chief Development Officer | 10,148 |
| Neil Harris Cohen | Director | 33,000 |
| Gwen A. Melincoff | Director | – |
| Alan Charles Moses | Director | – |
| Nissim Darvish | Director | 300 |
| Claude Nicaise | Director | – |
| Jill M. Quigley | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 10 employees / consultants.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 25, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 17, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 17, 2021 | Name change | Name changed from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. |
| Jan 13, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 15, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 8, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 3, 2015 | Name change | Name changed from BioCancell Ltd. to Anchiano Therapeutics Ltd. |
| Jan 2, 2013 | Deregistration | Termination of SEC registration (Form 15) |
| Jan 24, 2012 | Merger | Registration of securities for a merger or exchange offer (S-4) |